Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1912 in B-cell lymphoma
NCT05113069Phase 1Enrolling by invitation
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2021
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-A1912 in B cell lymphoma, sponsored by Hengrui Therapeutics. Primary endpoints: Adverse Events, Dose Limiting Toxicity and 2 more. Started Dec 2021; status: enrolling by invitation.
02
Drugs
SHR-A1912
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT05113069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05113069.